stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) Revenue
Perrigo Company plc's revenue for fiscal 2025 was $4.3B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $4.1B. Over the past ten years it has ranged from $2.6B (fiscal 2015) to $5.3B (fiscal 2016); the current reading is higher than 50% of that period. Perrigo Company plc ranks 8th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.3B | (2.75%) |
| FY2024 | $4.4B | (6.06%) |
| FY2023 | $4.7B | 4.58% |
| FY2022 | $4.5B | 7.56% |
| FY2021 | $4.1B | 1.24% |
| FY2020 | $4.1B | 5.64% |
| FY2019 | $3.9B | (18.21%) |
| FY2018 | $4.7B | (4.34%) |
| FY2017 | $4.9B | (6.33%) |
| FY2016 | $5.3B | 100.62% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $988.6M | (3.34%) |
| Jun 2026 | $1.0B | 5.53% |
| Mar 2026 | $969.2M | (12.65%) |
| Dec 2025 | $1.1B | 6.35% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc | $4.1B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| ANIP ANI Pharmaceuticals, Inc. compare | $1.0B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. compare | $368.3M |
| ALVO Alvotech compare | $293.3M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PRGO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement